ArticleJournal of translational medicine2025
Integrating genetics and transcriptome analyses identify potential biomarkers and immune interactions in metabolic syndrome-related sarcopenia.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Age-related adiponectin resistance in human skeletal muscle dysfunction: in vivo and in vitro evidence.Journal of translational medicine · 2026Article
- From mouth to muscle: mechanistic and interventional perspectives on the tongue-coating microbiome in sarcopenia.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIncreasing evidence has indicated that metabolic syndrome (MetS) exists in a close link with sarcopenia; however, the potential mechanism and biomarkers between them remain uninvestigated. This study leverages integrative genetics and transcriptome to identify potential biomarkers and immune interactions in MetS-related sarcopenia.
methodsWe used genome-wide association studies summary statistics for linkage disequilibrium score regression and MiXeR analyses to explore shared genetic architecture between MetS and sarcopenia-related traits. Causal associations were assessed via Mendelian randomization (MR), causal analysis using the summary effect, and summary data-based MR. Cross-phenotype association analysis identified pleiotropic variants, while transcriptome-wide association study revealed shared pleiotropic genes. Single-cell RNA sequencing mapped gene distribution across immune cells and intercellular communication. A clinical predictive model and MetS animal model validated the pleiotropic genes.
resultsLDSC analyses uncovered an aggregate group of 13 pairs demonstrating notable genetic correlations. A significant genetic overlap took place between MetS and sarcopenia-related traits. The causal association of MetS with WP and ALM were found. Furthermore, we determined 79 shared risk novel SNPs and 9 pleiotropic genes. These genes had a strong connection to immune cell infiltration, immune-related markers, and immun-related processes. We demonstrated varying levels of gene expression across different immune cell types using scRNA-seq data. Nine genes were selected for developing a clinical predictive model. For the predictive chart used to predict binary risks, the area under the curve in the training data was 0.75, and in the validation data it was 0.72. Finally, five genes were confirmed in the MetS animal model based on mRNA expression level.
conclusionThis research offers compelling proof of a shared genetic architecture and uncovered immune interactions between MetS and sarcopenia. Our unique innovation reveals the comorbidity mechanism of metabolic syndrome and sarcopenia from a genetic perspective. The discovery of pleiotropic genes provided potential targets for intervention in MetS-related sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.